Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia

Journal of Critical Care

Volumn 26, Issue 3, 2011, Pages 287-294

  Lee, Jae Hyuk ^a   Kim, Jooyeong ^b   Kim, Kyuseok ^a   Jo, You Hwan ^a   Rhee, JoongEui ^a   Kim, Tae Youn ^a   Na, Sang Hoon ^b   Hwang, Seung Sik ^c  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Inha University School of Medicine   (South Korea)

Author keywords

Albumin; C reactive protein; C5rtfommunity acquired pneumonia; Prognosis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; HYPERTENSIVE FACTOR;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ARTIFICIAL VENTILATION; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA SEVERITY INDEX; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ALBUMINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79956348453     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2010.10.007     Document Type: Article

References (33)

1. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
2. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
3. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382.
4. Angus D.C., Marrie T.J., Obrosky D.S., et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002, 166:717-723.
5. Ewig S., de Roux A., Bauer T., et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004, 59:421-427.
6. Menendez R., Martinez R., Reyes S., et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009, 64:587-591.
7. Chalmers J.D., Singanayagam A., Scally C., et al. Admission d-dimer can identify low-risk patients with community-acquired pneumonia. Ann Emerg Med 2009, 53:633-638.
8. Huang D.T., Weissfeld L.A., Kellum J.A., et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 52 2008, e42:48-58.
9. Mira J.P., Max A., Burgel P.R. The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy. Crit Care 12 Suppl 2008, 6:S5.
10. Chalmers J.D., Singanayagam A., Hill A.T. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008, 121:219-225.
11. Castell J.V., Gomez-Lechon M.J., David M., et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990, 12:1179-1186.
12. Dominguez de Villota E., Mosquera J.M., Rubio J.J., et al. Association of a low serum albumin with infection and increased mortality in critically ill patients. Intensive Care Med 1980, 7:19-22.
13. Artero A., Zaragoza R., Camarena J.J., et al. Prognostic factors of mortality in patients with community-acquired bloodstream infection with severe sepsis and septic shock. J Crit Care 2010.
14. Hedlund J.U., Hansson L.O., Ortqvist A.B. Hypoalbuminemia in hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995, 155:1438-1442.
15. Kaysar M., Augustine T., Jim L., et al. Predictors of length of stay between the young and aged in hospitalized community-acquired pneumonia patients. Geriatr Gerontol Int 2008, 8:227-233.
16. Apolinario Hidalgo R., Suarez Cabrera M., Geijo Martinez M.P., et al. [Prognostic factors in community acquired pneumonia. Prospective multicenter study in internal medical departments]. An Med Interna 2007, 24:467-472.
17. Yap F.H., Joynt G.M., Buckley T.A., et al. Association of serum albumin concentration and mortality risk in critically ill patients. Anaesth Intensive Care 2002, 30:202-207.
18. de Mutsert R., Grootendorst D.C., Indemans F., et al. Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition. J Ren Nutr 2009, 19:127-135.
19. Meziani F., Kremer H., Tesse A., et al. Human serum albumin improves arterial dysfunction during early resuscitation in mouse endotoxic model via reduced oxidative and nitrosative stresses. Am J Pathol 2007, 171:1753-1761.
20. Yao X., Miao W., Li M., et al. Protective effect of albumin on VEGF and brain edema in acute ischemia in rats. Neurosci Lett 2010, 472:179-183.
21. Lang J.D., Figueroa M., Chumley P., et al. Albumin and hydroxyethyl starch modulate oxidative inflammatory injury to vascular endothelium. Anesthesiology 2004, 100:51-58.
22. Jo S, Kim K, Jung K, et al.: The effects of incorporating a pneumonia severity index in the admission protocol for community-acquired pneumonia. J Emerg Med In Press, 2010.
23. Hanley J.A., McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148:839-843.
24. Jo S, Kim K, Jung K, et al.: The Effects of Incorporating a Pneumonia Severity Index in the Admission Protocol for Community-Acquired Pneumonia. J Emerg Med, In Press, 2010.
25. Carratala J., Fernandez-Sabe N., Ortega L., et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005, 142:165-172.
26. Marrie T.J., Lau C.Y., Wheeler S.L., et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000, 283:749-755.
27. Marras T.K., Gutierrez C., Chan C.K. Applying a prediction rule to identify low-risk patients with community-acquired pneumonia. Chest 2000, 118:1339-1343.
28. Buising K.L., Thursky K.A., Black J.F., et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 2006, 61:419-424.
29. Jeong KY, Kim K, Kim TY, et al.: Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia. Emerg Med J, In Press.
30. Mueller C., Laule-Kilian K., Scholer A., et al. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med 2005, 258:391-393.
31. Christ-Crain M., Breidthardt T., Stolz D., et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med 2008, 264:166-176.
32. Thiem U., Niklaus D., Sehlhoff B., et al. C-reactive protein, severity of pneumonia and mortality in elderly, hospitalised patients with community-acquired pneumonia. Age Ageing 2009, 38:693-697.
33. Charles P.G., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008, 47:375-384.